AR031520A1 - Un compuesto inhibidor de aspartilo proteasa, una composicion que lo comprende y un metodo para tratar un paciente con dicha composicion - Google Patents
Un compuesto inhibidor de aspartilo proteasa, una composicion que lo comprende y un metodo para tratar un paciente con dicha composicionInfo
- Publication number
- AR031520A1 AR031520A1 ARP000102852A ARP000102852A AR031520A1 AR 031520 A1 AR031520 A1 AR 031520A1 AR P000102852 A ARP000102852 A AR P000102852A AR P000102852 A ARP000102852 A AR P000102852A AR 031520 A1 AR031520 A1 AR 031520A1
- Authority
- AR
- Argentina
- Prior art keywords
- hiv
- composition
- compounds
- relates
- activity
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
- C07C311/15—Sulfonamides having sulfur atoms of sulfonamide groups bound to carbon atoms of six-membered aromatic rings
- C07C311/16—Sulfonamides having sulfur atoms of sulfonamide groups bound to carbon atoms of six-membered aromatic rings having the nitrogen atom of at least one of the sulfonamide groups bound to hydrogen atoms or to an acyclic carbon atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D493/00—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system
- C07D493/02—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system in which the condensed system contains two hetero rings
- C07D493/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
- A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/357—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having two or more oxygen atoms in the same ring, e.g. crown ethers, guanadrel
- A61K31/36—Compounds containing methylenedioxyphenyl groups, e.g. sesamin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
- C07C311/15—Sulfonamides having sulfur atoms of sulfonamide groups bound to carbon atoms of six-membered aromatic rings
- C07C311/16—Sulfonamides having sulfur atoms of sulfonamide groups bound to carbon atoms of six-membered aromatic rings having the nitrogen atom of at least one of the sulfonamide groups bound to hydrogen atoms or to an acyclic carbon atom
- C07C311/18—Sulfonamides having sulfur atoms of sulfonamide groups bound to carbon atoms of six-membered aromatic rings having the nitrogen atom of at least one of the sulfonamide groups bound to hydrogen atoms or to an acyclic carbon atom to an acyclic carbon atom of a hydrocarbon radical substituted by nitrogen atoms, not being part of nitro or nitroso groups
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
- C07C311/22—Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound oxygen atoms
- C07C311/29—Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound oxygen atoms having the sulfur atom of at least one of the sulfonamide groups bound to a carbon atom of a six-membered aromatic ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
- C07C311/30—Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound nitrogen atoms, not being part of nitro or nitroso groups
- C07C311/37—Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound nitrogen atoms, not being part of nitro or nitroso groups having the sulfur atom of at least one of the sulfonamide groups bound to a carbon atom of a six-membered aromatic ring
- C07C311/38—Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound nitrogen atoms, not being part of nitro or nitroso groups having the sulfur atom of at least one of the sulfonamide groups bound to a carbon atom of a six-membered aromatic ring having sulfur atoms of sulfonamide groups and amino groups bound to carbon atoms of six-membered rings of the same carbon skeleton
- C07C311/39—Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound nitrogen atoms, not being part of nitro or nitroso groups having the sulfur atom of at least one of the sulfonamide groups bound to a carbon atom of a six-membered aromatic ring having sulfur atoms of sulfonamide groups and amino groups bound to carbon atoms of six-membered rings of the same carbon skeleton having the nitrogen atom of at least one of the sulfonamide groups bound to hydrogen atoms or to an acyclic carbon atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D317/00—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms
- C07D317/08—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3
- C07D317/44—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 ortho- or peri-condensed with carbocyclic rings or ring systems
- C07D317/46—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 ortho- or peri-condensed with carbocyclic rings or ring systems condensed with one six-membered ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C2601/00—Systems containing only non-condensed rings
- C07C2601/06—Systems containing only non-condensed rings with a five-membered ring
- C07C2601/08—Systems containing only non-condensed rings with a five-membered ring the ring being saturated
Abstract
La presente invencion se relaciona con un compuesto inhibidor de aspartil proteasa (1). En una modalidad, esta invencion se relaciona con una nueva clase de inhibidores de aspartil proteasa HIV caracterizada por aspectos estructurales y fisicoquímicos específicos. Esta invencion también se relaciona con composiciones farmacéuticas que comprende estos compuestos. Los compuestos y composiciones farmacéuticas de esta invencion son particularmente utiles para inhibir la actividad de proteasa HIV-1 y HIV-2 y consecuentemente, pueden ser utilizados ventajosamente como agentes antivirales contra los virus HIV-1 y HIV-2. Esta invencion también se relaciona con métodos para inhibir la actividad de la aspartil proteasa HIV utilizando estos compuestos de la invencion y métodos para separar compuestos para actividad anti-HIV.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US13907099P | 1999-06-11 | 1999-06-11 | |
US19021100P | 2000-03-17 | 2000-03-17 |
Publications (1)
Publication Number | Publication Date |
---|---|
AR031520A1 true AR031520A1 (es) | 2003-09-24 |
Family
ID=26836833
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ARP000102852A AR031520A1 (es) | 1999-06-11 | 2000-06-07 | Un compuesto inhibidor de aspartilo proteasa, una composicion que lo comprende y un metodo para tratar un paciente con dicha composicion |
Country Status (31)
Country | Link |
---|---|
EP (2) | EP1194404B1 (es) |
JP (2) | JP4503896B2 (es) |
KR (1) | KR100762188B1 (es) |
CN (2) | CN100516034C (es) |
AR (1) | AR031520A1 (es) |
AT (2) | ATE325091T1 (es) |
AU (1) | AU779994B2 (es) |
BR (1) | BR0011745A (es) |
CA (1) | CA2380858C (es) |
CO (1) | CO5160337A1 (es) |
CY (1) | CY1112632T1 (es) |
CZ (1) | CZ303052B6 (es) |
DE (1) | DE60027722T2 (es) |
DK (2) | DK1686113T3 (es) |
ES (2) | ES2263478T3 (es) |
HK (1) | HK1046899B (es) |
HU (1) | HUP0300385A3 (es) |
IL (3) | IL146918A0 (es) |
MX (1) | MXPA01012808A (es) |
MY (1) | MY137777A (es) |
NO (1) | NO323951B1 (es) |
NZ (1) | NZ516003A (es) |
PE (1) | PE20010230A1 (es) |
PL (1) | PL210227B1 (es) |
PT (2) | PT1194404E (es) |
SI (1) | SI1194404T1 (es) |
TN (1) | TNSN00129A1 (es) |
TR (3) | TR200200407T2 (es) |
TW (3) | TWI299000B (es) |
WO (1) | WO2000076961A1 (es) |
ZA (1) | ZA200110177B (es) |
Families Citing this family (28)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1086076B1 (en) | 1998-06-19 | 2004-12-22 | Vertex Pharmaceuticals Incorporated | Sulfonamide inhibitors of aspartyl protease |
AR031520A1 (es) * | 1999-06-11 | 2003-09-24 | Vertex Pharma | Un compuesto inhibidor de aspartilo proteasa, una composicion que lo comprende y un metodo para tratar un paciente con dicha composicion |
ES2275866T3 (es) * | 2001-02-14 | 2007-06-16 | Tibotec Pharmaceuticals Ltd. | 2-(aminosustituido)-benzotiazol-sulfonamidas de amplio esprecto inhibidoras de la proteasa de vih. |
US7285566B2 (en) * | 2002-01-07 | 2007-10-23 | Erickson John W | Resistance-repellent retroviral protease inhibitors |
MY142238A (en) * | 2002-03-12 | 2010-11-15 | Tibotec Pharm Ltd | Broadspectrum substituted benzimidazole sulfonamide hiv protease inhibitors |
CA2481449A1 (en) * | 2002-04-26 | 2003-11-06 | Gilead Sciences, Inc. | Method and compositions for identifying anti-hiv therapeutic compounds |
US6632816B1 (en) * | 2002-12-23 | 2003-10-14 | Pharmacor Inc. | Aromatic derivatives as HIV aspartyl protease inhibitors |
EP1638960A4 (en) * | 2003-06-27 | 2009-04-01 | Smithkline Beecham Corp | PREPARATION OF CHEMICAL COMPOUNDS |
JP5144930B2 (ja) | 2003-08-18 | 2013-02-13 | ハー・ルンドベック・アクチエゼルスカベット | トランス−1−(6−クロロ−3−フェニルインダン−1−イル)−3,3−ジメチルピペラジン |
EP1699455B1 (en) * | 2003-12-15 | 2013-05-08 | Merck Sharp & Dohme Corp. | Heterocyclic aspartyl protease inhibitors |
MXPA06010365A (es) | 2004-03-11 | 2007-05-04 | Sequoia Pharmaceuticals Inc | Inhibidores de proteasa retrovirales repelentes a la resistencia. |
TWI383975B (zh) | 2004-03-31 | 2013-02-01 | Tibotec Pharm Ltd | 製備(3R,3aS,6aR)六氫-呋喃并〔2,3-b〕呋喃-3-醇之方法 |
US7388008B2 (en) | 2004-08-02 | 2008-06-17 | Ambrilia Biopharma Inc. | Lysine based compounds |
TWI453198B (zh) | 2005-02-16 | 2014-09-21 | Lundbeck & Co As H | 製造反式-1-((1r,3s)-6-氯基-3-苯基茚滿-1-基) -3 , 3 -二甲基六氫吡與其鹽類之方法及製造4-((1r , 3s)-6 -氯基-3-苯基茚滿-1-基 )-1,2,2-三甲基六氫吡與其鹽類之方法 |
TWI376373B (en) | 2005-02-16 | 2012-11-11 | Lundbeck & Co As H | Crystalline base of a pharmaceutical compound |
JP2008533017A (ja) * | 2005-03-11 | 2008-08-21 | スミスクライン ビーチャム コーポレーション | Hivプロテアーゼ阻害薬 |
JP2009517412A (ja) | 2005-11-30 | 2009-04-30 | アンブリリア バイオファーマ インコーポレイテッド | アスパルチルプロテアーゼ阻害物質のリジンベースのプロドラッグ及びその調製方法 |
US20080070910A1 (en) * | 2006-07-24 | 2008-03-20 | Desai Manoj C | Therapeutic compounds and methods |
BRPI0718706B8 (pt) | 2006-11-09 | 2021-05-25 | Janssen R & D Ireland | métodos para a preparação de hexa-hidrofuro[2,3- b]furan-3-ol |
US9808527B2 (en) * | 2006-11-21 | 2017-11-07 | Purdue Research Foundation | Methods and compositions for treating HIV infections |
MX2009011574A (es) | 2007-04-27 | 2009-11-09 | Tibotec Pharm Ltd | Metodos para la preparacion de derivados de n-isobutil-n-(2-hidrox i-3-amino-4-fenilbutil)-p-nitrobencensulfonilamida. |
GB2452952A (en) * | 2007-09-20 | 2009-03-25 | Npil Pharmaceuticals | N-[2-Hydroxy-3-(hydroxycarbonylamino)-3-methyl]-N-methyl-sulphonamide derivatives via N-[2-oxo-3-(hydroxycarbonylamino)-3-methyl]-N-methyl-imine skeleton |
US8592487B2 (en) | 2007-10-26 | 2013-11-26 | Concert Pharmaceuticals, Inc. | Deuterated darunavir |
RU2569058C2 (ru) * | 2009-09-22 | 2015-11-20 | Тиботек Фармасьютикалз | Лечение и предупреждение вич-инфекции |
WO2011061590A1 (en) | 2009-11-17 | 2011-05-26 | Hetero Research Foundation | Novel carboxamide derivatives as hiv inhibitors |
CN103193570B (zh) * | 2013-04-09 | 2014-01-22 | 湖北来凤腾升香料化工有限公司 | 一种羟基高选择性保护方法 |
JPWO2016039403A1 (ja) * | 2014-09-11 | 2017-06-29 | 塩野義製薬株式会社 | 持続性hivプロテアーゼ阻害剤 |
US11116737B1 (en) | 2020-04-10 | 2021-09-14 | University Of Georgia Research Foundation, Inc. | Methods of using probenecid for treatment of coronavirus infections |
Family Cites Families (19)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE3635907A1 (de) * | 1986-10-22 | 1988-04-28 | Merck Patent Gmbh | Hydroxy-aminosaeurederivate |
CA2032259A1 (en) * | 1989-12-18 | 1991-06-19 | Wayne J. Thompson | Hiv protease inhibitors useful for the treatment of aids |
US5475013A (en) * | 1990-11-19 | 1995-12-12 | Monsanto Company | Retroviral protease inhibitors |
ATE296625T1 (de) * | 1990-11-19 | 2005-06-15 | Monsanto Co | Retrovirusprotease inhibitoren |
DK0656887T3 (da) * | 1992-08-25 | 1999-07-05 | Searle & Co | Hydroxyethylaminosulfonamider til anvendelse som inhibitorer af retrovirale proteaser |
US5723490A (en) * | 1992-09-08 | 1998-03-03 | Vertex Pharmaceuticals Incorporated | THF-containing sulfonamide inhibitors of aspartyl protease |
IS2334B (is) * | 1992-09-08 | 2008-02-15 | Vertex Pharmaceuticals Inc., (A Massachusetts Corporation) | Aspartyl próteasi hemjari af nýjum flokki súlfonamíða |
DE69326077T2 (de) * | 1992-10-30 | 2000-01-27 | Searle & Co | Sulfonylalkanoylaminohydroxyethylaminosulfaminsäuren verwendbar als inhibitoren retroviraler proteasen |
AU7669794A (en) * | 1993-08-24 | 1995-03-21 | G.D. Searle & Co. | Hydroxyethylamino sulphonamides useful as retroviral protease inhibitors |
EP0804428B1 (en) * | 1995-01-20 | 2007-12-26 | G.D. Searle LLC. | Bis-sulfonamide hydroxyethylamino retroviral protease inhibitors |
US5756533A (en) * | 1995-03-10 | 1998-05-26 | G.D. Searle & Co. | Amino acid hydroxyethylamino sulfonamide retroviral protease inhibitors |
HUP9800518A3 (en) * | 1995-03-10 | 1998-09-28 | G D Searle & Co Chicago | Heterocyclecarbonyl amino acid hydroxyethylamino sulfonamide retroviral protease inhibitors |
US6150556A (en) * | 1995-03-10 | 2000-11-21 | G. D. Dearle & Co. | Bis-amino acid hydroxyethylamino sulfonamide retroviral protease inhibitors |
US5705500A (en) * | 1995-03-10 | 1998-01-06 | G.D. Searle & Co. | Sulfonylalkanoylamino hydroxyethylamino sulfonamide retroviral protease inhibitors |
US5691372A (en) * | 1995-04-19 | 1997-11-25 | Vertex Pharmaceuticals Incorporated | Oxygenated-Heterocycle containing sulfonamide inhibitors of aspartyl protease |
US5753660A (en) * | 1995-11-15 | 1998-05-19 | G. D. Searle & Co. | Substituted sulfonylalkanoylamino hydroxyethylamino sulfonamide retroviral protease inhibitors |
GB9712504D0 (en) * | 1997-06-17 | 1997-08-20 | Dundee Teaching Hospitals Nhs | Thermal imaging method and apparatus |
AU9203898A (en) * | 1997-08-26 | 1999-03-16 | Wisconsin Alumni Research Foundation | Cyclosporin a conjugates and uses therefor |
AR031520A1 (es) * | 1999-06-11 | 2003-09-24 | Vertex Pharma | Un compuesto inhibidor de aspartilo proteasa, una composicion que lo comprende y un metodo para tratar un paciente con dicha composicion |
-
2000
- 2000-06-07 AR ARP000102852A patent/AR031520A1/es active IP Right Grant
- 2000-06-08 TR TR2002/00407T patent/TR200200407T2/xx unknown
- 2000-06-08 TR TR2006/03871T patent/TR200603871T2/xx unknown
- 2000-06-08 TW TW093114799A patent/TWI299000B/zh not_active IP Right Cessation
- 2000-06-08 SI SI200030872T patent/SI1194404T1/sl unknown
- 2000-06-08 CZ CZ20014431A patent/CZ303052B6/cs not_active IP Right Cessation
- 2000-06-08 CN CNB008104395A patent/CN100516034C/zh not_active Expired - Fee Related
- 2000-06-08 PT PT00941279T patent/PT1194404E/pt unknown
- 2000-06-08 CA CA2380858A patent/CA2380858C/en not_active Expired - Fee Related
- 2000-06-08 DE DE60027722T patent/DE60027722T2/de not_active Expired - Lifetime
- 2000-06-08 CO CO00042752A patent/CO5160337A1/es unknown
- 2000-06-08 AT AT00941279T patent/ATE325091T1/de active
- 2000-06-08 DK DK06009072.7T patent/DK1686113T3/da active
- 2000-06-08 EP EP00941279A patent/EP1194404B1/en not_active Expired - Lifetime
- 2000-06-08 HU HU0300385A patent/HUP0300385A3/hu unknown
- 2000-06-08 MX MXPA01012808A patent/MXPA01012808A/es active IP Right Grant
- 2000-06-08 TW TW096138754A patent/TWI318116B/zh not_active IP Right Cessation
- 2000-06-08 AT AT06009072T patent/ATE534622T1/de active
- 2000-06-08 ES ES00941279T patent/ES2263478T3/es not_active Expired - Lifetime
- 2000-06-08 DK DK00941279T patent/DK1194404T3/da active
- 2000-06-08 PE PE2000000573A patent/PE20010230A1/es not_active Application Discontinuation
- 2000-06-08 NZ NZ516003A patent/NZ516003A/xx not_active IP Right Cessation
- 2000-06-08 TN TNTNSN00129A patent/TNSN00129A1/fr unknown
- 2000-06-08 PT PT06009072T patent/PT1686113E/pt unknown
- 2000-06-08 TR TR2002/02528T patent/TR200202528T2/xx unknown
- 2000-06-08 AU AU56006/00A patent/AU779994B2/en not_active Ceased
- 2000-06-08 IL IL14691800A patent/IL146918A0/xx unknown
- 2000-06-08 MY MYPI20002595A patent/MY137777A/en unknown
- 2000-06-08 WO PCT/US2000/015781 patent/WO2000076961A1/en active Application Filing
- 2000-06-08 KR KR1020017016293A patent/KR100762188B1/ko not_active IP Right Cessation
- 2000-06-08 TW TW089111145A patent/TW593248B/zh not_active IP Right Cessation
- 2000-06-08 ES ES06009072T patent/ES2375823T3/es not_active Expired - Lifetime
- 2000-06-08 EP EP06009072A patent/EP1686113B1/en not_active Expired - Lifetime
- 2000-06-08 BR BR0011745-5A patent/BR0011745A/pt not_active Application Discontinuation
- 2000-06-08 CN CNA2008100096668A patent/CN101245058A/zh active Pending
- 2000-06-08 JP JP2001503821A patent/JP4503896B2/ja not_active Expired - Fee Related
- 2000-06-08 PL PL352830A patent/PL210227B1/pl not_active IP Right Cessation
-
2001
- 2001-12-04 IL IL146918A patent/IL146918A/en not_active IP Right Cessation
- 2001-12-10 NO NO20016034A patent/NO323951B1/no not_active IP Right Cessation
- 2001-12-11 ZA ZA200110177A patent/ZA200110177B/en unknown
-
2002
- 2002-09-23 HK HK02106939.9A patent/HK1046899B/zh not_active IP Right Cessation
-
2008
- 2008-09-08 JP JP2008230351A patent/JP2009046493A/ja not_active Withdrawn
-
2009
- 2009-12-09 IL IL202633A patent/IL202633A/en not_active IP Right Cessation
-
2012
- 2012-02-22 CY CY20121100182T patent/CY1112632T1/el unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AR031520A1 (es) | Un compuesto inhibidor de aspartilo proteasa, una composicion que lo comprende y un metodo para tratar un paciente con dicha composicion | |
ES2171670T3 (es) | Sulfonamidas que contienen heterociclos oxigenados como inhibidores de la aspartil proteasa. | |
ES2131589T3 (es) | Sulfonamidas inhibidoras de aspartil-proteasa del vih. | |
MX9307821A (es) | Nueva clase de inhibidores de proteasa aspartilo. | |
AP1717A (en) | Sulfonamide inhibitors of aspartyl protease. | |
ES2181882T3 (es) | Sulfonamidas inhibidoras de la aspartil-proteasa que contienen tetrahidrofurano (thf). | |
MX9403380A (es) | Inhibidores de proteasa de vih utiles para el tratamiento de sida. | |
ECSP066959A (es) | Compuestos macrociclicos como inhibidores de la replicación viral | |
ES2157437T3 (es) | Inhibidores de proteasas retrovirales de sulfonilalcanoilamino-hidroxietilamino-sulfonamida. | |
EE04376B1 (et) | Bis-aminohappe hüdroksüetüülamino-sulfoonamiidsedretroviirusliku proteaasi inhibiitorid | |
DE69811062T2 (de) | Polyaromatische antivirale zusammensetzungen | |
ES2183817T3 (es) | Inibidores de proteasas de parasatiso metazoarios. | |
DE69518840D1 (en) | N-(3-amino-2-hydroxybutyl)sulfonamid-derivate as hiv-protease-inhibitoren | |
PT1159278E (pt) | Inibidores de aspartil-protease | |
AR009935A1 (es) | Un compuesto efectivo para inhibir aspartilproteasa, composiciones que lo incorporan y metodos para prevenir o tratar infecciones con hiv | |
DE69909747D1 (de) | Pharmazeutische zusammensetzung, enthaltend peg-asparaginase, für die behandlung von hiv infektionen | |
ES2103577T3 (es) | Compuestos antiviricos de naftoquinona, composiciones que los contienen y utilizaciones de estos compuestos. | |
WO2002010124A3 (en) | Salt forms of an hiv protease inhibitor | |
NO992228D0 (no) | 1-(3-aminoindazol-5-yl)-3-fenylmetyl-syklisk urea egnet som HIV protease inhibitor | |
NO20024522L (no) | Sammensetninger med anti-hiv-aktivitet | |
AR013087A1 (es) | Forma v de amprenavir, su uso como compuesto antiviral, un proceso para prepararlo, y composiciones farmaceuticas que lo comprenden | |
MX9708057A (es) | Sulfonamidas que contienen thf inhibidoras de la aspartilproteasa. | |
MX9708055A (es) | Inhibidores de aspartil proteasa consistentes en sulfonamida que contiene heterociclo oxigenado. | |
MY135869A (en) | Inhibitors of aspartyl protease | |
TW200517112A (en) | Compounds and pharmaceutical composition for inhibiting HIV protease |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FG | Grant, registration |